Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201606-16 Development of HL217 eye drop as global new drug for the treatment of age-related macular degeneration(Others, Chemical) [2019-03-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

- To evaluate the safety of HL217 eye drop in administration in healthy adults in the UK (Phase 1) based on the results of non-clinical studies and mode of action studies including anti-angiogenesis by inhibiting VEGF and PDGF receptor expression or receptor binding mechanism.

- To license out HL217 eye drop to a global pharmaceutical company or to co-develop HL217 eye drop with partners

- To develop first AMD treatment drug as eye-drop formulation

Unmet Medical Need & Target Patients

Target patients

AMD (Age-related Macular Degeneration) patient: The proliferation of abnormal fragile blood vessels in the retina is stimulated by VEGF (vascular endothelial growth factor). AMD is one of the main reasons of vision loss in elderly people, if left untreated.

 

Unmet medical needs

Currently, drugs for AMD are inconvenient to use because they are intraocular injection formulations (Lucentis, Eyelia, and etc.). Intraocular injection can cause poor patient compliance and concerns of side-effects such as inflammation and infection. Also, expensive drug costs can be a burden to patients.

Status

- Nonclinical study results showed inhibitory effects of HL217 on angiogenesis factors. Mouse, rat, mini-pig and beagle dog models were used to evaluate anti-angiogenesis effects of HL217

- Nonclinical safety of HL217 was screened by mouse, rat, rabbit, and beagle dog models.

- MHRA (United Kingdom) approved phase 1 clinical trial application of HL217 to evaluate safety, tolerance and pharmacokinetic property in healthy male volunteers in Aug, 2016

Intellectual Property

- Basic patent has been granted in Korea and other countries.

- Usage patent has been submitted to Korea and other countries and it is now under examination, while it has been granted in some countries.

Competitive Advantages

- HL217 can be first ‘eye drop’ formulation to offer non-invasive and safe administration.

- HL217 can substitute current treatments or be used as co-administrated drug.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code